Cardlytics (CDLX)
(Delayed Data from NSDQ)
$11.59 USD
+0.07 (0.56%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $11.60 +0.02 (0.13%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Cardlytics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 309 | 299 | 267 | 187 | 210 |
Cost Of Goods | 179 | 186 | 164 | 124 | 131 |
Gross Profit | 130 | 113 | 103 | 63 | 79 |
Selling & Adminstrative & Depr. & Amort Expenses | 266 | 570 | 226 | 117 | 97 |
Income After Depreciation & Amortization | -136 | -458 | -123 | -54 | -17 |
Non-Operating Income | 3 | -6 | -1 | 2 | 1 |
Interest Expense | 2 | 3 | 13 | 3 | 1 |
Pretax Income | -135 | -467 | -136 | -55 | -17 |
Income Taxes | 0 | -1 | -8 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -135 | -465 | -129 | -55 | -17 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -135 | -465 | -129 | -55 | -17 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -34 | 41 | -73 | -35 | -10 |
Depreciation & Amortization (Cash Flow) | 102 | 499 | 50 | 19 | 8 |
Income After Depreciation & Amortization | -136 | -458 | -123 | -54 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 36.49 | 33.42 | 32.20 | 27.23 | 23.75 |
Diluted EPS Before Non-Recurring Items | -1.43 | -3.06 | -2.43 | -2.05 | -0.75 |
Diluted Net EPS (GAAP) | -3.69 | -13.92 | -3.99 | -2.04 | -0.72 |
Fiscal Year end for Cardlytics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 89.17 | 79.01 | 76.70 | 64.33 |
Cost Of Goods | NA | 49.68 | 43.16 | 46.19 | 39.81 |
Gross Profit | NA | 39.49 | 35.85 | 30.52 | 24.52 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 142.41 | 56.50 | 54.84 | 12.30 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -102.92 | -20.65 | -24.32 | 12.22 |
Non-Operating Income | NA | 2.93 | -2.40 | 1.39 | 1.39 |
Interest Expense | NA | 0.84 | 0.92 | 0.57 | 0.01 |
Pretax Income | NA | -100.84 | -23.97 | -23.51 | 13.61 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -100.84 | -23.97 | -23.51 | 13.61 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -100.84 | -23.97 | -23.51 | 13.61 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 39.45 | 37.98 | 34.88 | 36.73 |
Diluted EPS Before Non-Recurring Items | NA | -0.14 | -0.26 | -0.57 | -0.47 |
Diluted Net EPS (GAAP) | NA | -2.79 | -0.63 | -0.67 | 0.40 |